Seaport Therapeutics’ Series B financing was one of the largest rounds of funding in our recap of biotech financing news, which spans startups developing drugs for neurological diseases, cancer, immunology, and more.
Seaport Therapeutics’ drug candidates are delivered through the lymphatic system, an approach that could overcome some limitations of neuropsychiatric medicines, including products from Sage Therapeutics. The startup stems from the research of PureTech Health.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
5AM Ventures and RA Capital Management led the round. The company is developing hematopoietic stem cells engineered to be protected from targeted immunotherapies.
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.
PureTech, which has put itself squarely at the intersection of med tech and digital health innovation, has raised $55 million in a growth stage investment round, according to a company statement. It also added three senior partners from MIT and Harvard Medical School. It received the new funding with participation from Invesco Perpetual to […]